Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17190791
Zagórska A, et al. (2007) Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol 176, 89-100 17190791
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
sorbitol no change compared to control
KCl no change compared to control
hypotonic_buffer no change compared to control
H2O2 no change compared to control
TNF no change compared to control
phorbol_ester no change compared to control
vanadate no change compared to control
bumetanide no change compared to control
calyculin_A no change compared to control

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
PD184352 sorbitol inhibit treatment-induced increase
KCl no change compared to control
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester increase
vanadate increase
bumetanide no change compared to control
calyculin_A no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
PD184352 sorbitol inhibit treatment-induced increase
KCl no change compared to control
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester increase
vanadate increase
bumetanide no change compared to control
calyculin_A no change compared to control

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
PD184352 sorbitol inhibit treatment-induced increase
KCl no change compared to control
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester increase
vanadate increase
bumetanide no change compared to control
calyculin_A no change compared to control

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
PD184352 sorbitol inhibit treatment-induced increase
KCl no change compared to control
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester increase
vanadate increase
bumetanide no change compared to control
calyculin_A no change compared to control

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
sorbitol WNK1 (human) no effect upon treatment-induced increase
KCl increase
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester no change compared to control
vanadate no change compared to control
bumetanide no change compared to control
calyculin_A no change compared to control

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
sorbitol WNK1 (human) no effect upon treatment-induced increase
KCl increase
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester no change compared to control
vanadate no change compared to control
bumetanide no change compared to control
calyculin_A no change compared to control

T185-p - OSR1 (human)
Modsite: TRNKVRktFVGtPCW SwissProt Entrez-Gene
Orthologous residues
OSR1 (human): T185‑p, OSR1 (mouse): T185‑p, OSR1 (rat): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol WNK1 (human) increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

S325-p - OSR1 (human)
Modsite: VRRVPGssGRLHKtE SwissProt Entrez-Gene
Orthologous residues
OSR1 (human): S325‑p, OSR1 (mouse): S325‑p, OSR1 (rat): S325‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol WNK1 (human) increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
KCl increase slight increase
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester no change compared to control
vanadate no change compared to control
bumetanide no change compared to control
calyculin_A no change compared to control

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
KCl increase slight increase
hypotonic_buffer no change compared to control
H2O2 no change compared to control
IGF-1 no change compared to control
TNF no change compared to control
phorbol_ester no change compared to control
vanadate no change compared to control
bumetanide no change compared to control
calyculin_A no change compared to control

T231-p - STLK3 (human)
Modsite: tRNKVRktFVGtPCW SwissProt Entrez-Gene
Orthologous residues
STLK3 (human): T231‑p, STLK3 (mouse): T243‑p, STLK3 (rat): T240‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol WNK1 (human) increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

S371-p - STLK3 (human)
Modsite: VRRVPGssGHLHKTE SwissProt Entrez-Gene
Orthologous residues
STLK3 (human): S371‑p, STLK3 (mouse): S383‑p, STLK3 (rat): S380‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol WNK1 (human) increase

S15-p - WNK1 (human)
Modsite: KQSstPGsLFLsPPA SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S15‑p, WNK1 iso2 (human): S15‑p, WNK1 iso4 (human): , WNK1 iso5 (human): S15‑p, WNK1 (mouse): , WNK1 iso3 (mouse): , WNK1 (rat): , WNK1 (cow): S15‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase

S167-p - WNK1 (human)
Modsite: TSKDRPVsQPsLVGs SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S167‑p, WNK1 iso2 (human): S167‑p, WNK1 iso4 (human): , WNK1 iso5 (human): S167‑p, WNK1 (mouse): S165‑p, WNK1 iso3 (mouse): S165‑p, WNK1 (rat): S165‑p, WNK1 (cow): V172‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase

S382-p - WNK1 (human)
Modsite: kRAsFAKsVIGTPEF SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S382‑p, WNK1 iso2 (human): S382‑p, WNK1 iso4 (human): , WNK1 iso5 (human): S382‑p, WNK1 (mouse): S382‑p, WNK1 iso3 (mouse): S382‑p, WNK1 (rat): S382‑p, WNK1 (cow): S387‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE WNK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

S1261-p - WNK1 (human)
Modsite: AGRRFIVsPVPESRL SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S1261‑p, WNK1 iso2 (human): S1014‑p, WNK1 iso4 (human): S854‑p, WNK1 iso5 (human): S1513‑p, WNK1 (mouse): S1256‑p, WNK1 iso3 (mouse): S1514‑p, WNK1 (rat): S1007‑p, WNK1 (cow): S1274‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
OSR1 (human) Disrupts pull-down assay
STLK3 (human) Disrupts pull-down assay

T1848-p - WNK1 (human)
Modsite: KEGPVLAtsSGAGVF SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): T1848‑p, WNK1 iso2 (human): T1601‑p, WNK1 iso4 (human): T1441‑p, WNK1 iso5 (human): T2100‑p, WNK1 (mouse): T1843‑p, WNK1 iso3 (mouse): T2101‑p, WNK1 (rat): S1593‑p, WNK1 (cow): P1849‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase

S2012-p - WNK1 (human)
Modsite: sHLNGPssDPEAAFL SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S2012‑p, WNK1 iso2 (human): S1765‑p, WNK1 iso4 (human): S1605‑p, WNK1 iso5 (human): S2264‑p, WNK1 (mouse): S2007‑p, WNK1 iso3 (mouse): S2265‑p, WNK1 (rat): S1756‑p, WNK1 (cow): S2008‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol no change compared to control

S2029-p - WNK1 (human)
Modsite: DVDDGsGsPHsPHQL SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S2029‑p, WNK1 iso2 (human): S1782‑p, WNK1 iso4 (human): S1622‑p, WNK1 iso5 (human): S2281‑p, WNK1 (mouse): S2024‑p, WNK1 iso3 (mouse): S2282‑p, WNK1 (rat): S1773‑p, WNK1 (cow): S2025‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol no change compared to control

S2032-p - WNK1 (human)
Modsite: DGsGsPHsPHQLssK SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S2032‑p, WNK1 iso2 (human): S1785‑p, WNK1 iso4 (human): S1625‑p, WNK1 iso5 (human): S2284‑p, WNK1 (mouse): S2027‑p, WNK1 iso3 (mouse): S2285‑p, WNK1 (rat): S1776‑p, WNK1 (cow): S2028‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol no change compared to control

S2372-p - WNK1 (human)
Modsite: SNLQKsIsNPPGSNL SwissProt Entrez-Gene
Orthologous residues
WNK1 (human): S2372‑p, WNK1 iso2 (human): S2125‑p, WNK1 iso4 (human): S1965‑p, WNK1 iso5 (human): S2624‑p, WNK1 (mouse): S2367‑p, WNK1 iso3 (mouse): S2625‑p, WNK1 (rat): S2116‑p, WNK1 (cow): S2367‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorbitol increase